There’s some promising evidence on the use of miRNA, like 371, in testicular cancer patients. I don’t think there’s been quite enough of, you know, data that’s come out on that so far, especially in comparison to ctDNA, which there’s also limited data on that. So I don’t think we quite know. You know, each of them kind of have their limitations...
There’s some promising evidence on the use of miRNA, like 371, in testicular cancer patients. I don’t think there’s been quite enough of, you know, data that’s come out on that so far, especially in comparison to ctDNA, which there’s also limited data on that. So I don’t think we quite know. You know, each of them kind of have their limitations. I don’t think we know in maybe which patients. I think miRNA isn’t very useful in teratomas, for example. So I think there definitely needs to be more investigation both into ctDNA by itself, into miRNA by itself, and then eventually a study where we’re looking at them in patients that are getting both at the same time. And maybe we can tease out in what populations, whether it’s based on tumor histology or stage of disease, maybe one of them’s a more effective tool than the other, or maybe they’ll be used in tandem, which would, you know, be good for the patients, especially, you know, testicular cancer patients that’s generally a younger age of the patient, so subjecting them to repeat CAT scans, imaging, you know, radiation, it would be nice to avoid if we had a more effective tool.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
